Jay Nelson, director of the OHSU Vaccine & Gene Therapy Institute, has been awarded a $10 million contract from the National Institutes of Health for discovery work on new ways to improve vaccines. They were one of seven groups awarded such contracts. Vaccine adjuvants are compounds that bolster the innate immune response, essentially super-charging the vaccine. While adjuvants show great promise in improving vaccines and fighting disease, currently just three are in use–scientists at VGTI and other institutions will begin to screen millions of molecules in search of more. Read the NIH press release here.
Welcome to the Research News Blog
OHSU Research News is your portal to information about all things research at Oregon Health & Science University. Visit often for updates on events, discoveries, and important funding information.
Recent Blog Posts
- K12 career development opportunity for research in women’s health, sex/gender differences
- Outgoing Subawards: Best practices, West Campus, June 27
- Applying for foundation funding? Check out the President’s List!
- Anthony@Pulmonary Medicine Journal on OHSU scientist Ilya Ivlev finds patient decision aids can have big impact
- Genie on OHSU scientist Jon Hennebold identifies key pathway in ovulation
- Mike Powers on OHSU scientist Jon Hennebold identifies key pathway in ovulation
awards basic research brown bag cancer career development clinical research collaboration community conference cores Discoveries eIRB event events funding funding focus funding opportunities Funding Opportunity graduate students internal funding IRB Notes junior faculty lecture Limited Submission NIH NIH News OCTRI OHSU faculty OHSU Knight Cancer Institute OHSU Researchers ONPRC postdoctoral fellows research Research Administration research career development research integrity Research Resources research week seminar technology training translational research TTBD visiting speaker workshop